Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176139 | 0.86 | SLC22A4 (0.35) | SLC22A4 | |
| Alcohol SCHEMBL4168131 | 0.83 | SLC22A4 (0.36) | SLC22A4 | |
| SCHEMBL13778550 | 0.78 | SLC22A4 (0.34) | SLC22A4 | |
| SCHEMBL1339411 | 0.70 | SLC22A4 (0.35) | SLC22A4 | |
| SCHEMBL4767936 | 0.69 | — | — | |
| SCHEMBL1339493 | 0.68 | CYP19A1 (0.48) | SLC22A4 | |
| SCHEMBL12663292 | 0.67 | NOS3 (0.37) | — | |
| SCHEMBL14625844 | 0.63 | — | — | |
| SCHEMBL1341654 | 0.61 | SLC22A4 (0.31) | SLC22A4 | |
| SCHEMBL7579122 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404979-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2023-12-21 | — | — | US | claimed |
| EP-4031000-A1 | SYSTEMS AND METHODS FOR DETECTION AND PREVENTION OF EMERGENCE OF AGITATION | Bioxcel Therapeutics, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220202373-A1 | SYSTEMS AND METHODS OF USING MACHINE LEARNING TO DETECT AND PREDICT EMERGENCE OF AGITATION BASED ON SYMPATHETIC NERVOUS SYSTEM ACTIVITIES | BIOXCEL THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | US | claimed |
| CN-114667095-A | System and method for detecting and preventing irritability occurrences | 比奥克斯塞尔医疗股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2022093767-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| US-7390829-B2 | Alpha-2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-06-24 | — | — | US | claimed |
| US-20070004789-A1 | Alpha-2adrenergic agonists | ALLERGAN, INC. | 2007-01-04 | — | — | US | claimed |
| US-20250325521-A1 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | BIOXCEL THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20240252470-A1 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | OAKTREE FUND ADMINISTRATION, LLC | 2024-08-01 | — | — | US | disclosed |
| EP-4371554-A2 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | BioXcel Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4368169-A2 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | Bioxcel Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11931340-B2 | Use of sublingual dexmedetomidine for the treatment of agitation | BIOXCEL THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3562486-B1 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | BIOXCEL THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-7390829-B2 | Alpha-2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2007005177-A1 | ALPHA-2 ADRENERGIC AGONISTS FOR THE TREATMENT OF PAIN | ALLERGAN, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005174-A2 | 4- (3 -HYDROXY- AND 3-AMINOMETHYL-CYCLOHEXEN-3-YLMETHYL) 1, 3-DIHYDROIMDAZOLE-2-THIONE DERIVATIVES AS ALPHA-2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005174-A2 | 4- (3 -HYDROXY- AND 3-AMINOMETHYL-CYCLOHEXEN-3-YLMETHYL) 1, 3-DIHYDROIMDAZOLE-2-THIONE DERIVATIVES AS ALPHA-2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004789-A1 | Alpha-2adrenergic agonists | ALLERGAN, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004789-A1 | Alpha-2adrenergic agonists | ALLERGAN, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004789-A1 | Alpha-2adrenergic agonists | ALLERGAN, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004789-A1 | Alpha-2adrenergic agonists | ADRA2A, ADRB2, ADRA2C | SLC22A4 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.